Notable Analyst Rating Changes 12/10: (CELG) (GERN) (ARIA) Upgraded; (DGX) (HME) (CHL) Downgraded

December 10, 2013 10:42 AM EST
Credit Suisse moves Celgene (Nasdaq: CELG) from Neutral to Outperform.

Needham & Company boosts Geron Corporation (Nasdaq: GERN) from Hold to Buy with a price target of $10. Click Here for more color.

Stifel Nicolaus raises ARIAD Pharmaceuticals (Nasdaq: ARIA) from Hold to Buy with a $7 price target.

KLR Group upgrades Goodrich Petroleum (NYSE: GDP) from Accumulate to Buy, while maintaining its price target at $26.

For daily real-time Upgrades go to

BofA/Merrill Lynch cuts Quest Diagnostics (NYSE: DGX) from Buy to Underperform.

Morgan Stanley drops Home Properties (NYSE: HME) from Equalweight to Underweight.

Barclays slashes China Mobile (NYSE: CHL) from Overweight to Underweight.

Longbow Research lowers Old Dominion Freight Line (Nasdaq: ODFL) from Buy to Neutral and removed its $52 price target.

For daily real-time Downgrades go to

Zulily, Inc (Nasdaq: ZU) started by a handful today:
  • BofA/Merrill Lynch at Neutral and $39 price target;

  • William Blair at Outperform;

  • Citi with a Neutral rating and price target of $38;

  • RBC Capital with a Sector Perform and $40 price target; and

  • Goldman Sachs at Neutral and $36 price target.
Jefferies initiates Rambus Inc. (Nasdaq: RMBS) with a Buy and price target of $13. Click Here for more color.

Credit Suisse initiates Allegion (NYSE: ALLE) at Outperform and price target of $48.

Morgan Stanley starts Relypsa, Inc. (Nasdaq: RLYP) with an Overweight rating and price target of $57.

For daily real-time New Coverage go to

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Credit Suisse, Stifel, William Blair, Citi, Morgan Stanley, Jefferies & Co, Merrill Lynch, Needham & Company, Bank of America, RBC Capital, Barclays, Longbow Research, Notable Analyst Rating Changes

Add Your Comment